5 studies found for:    IL7R
Show Display Options
Rank Status Study
1 Completed IL-7 Receptor Polymorphisms and Immune Recovery With HAART
Condition: HIV Infections
Intervention:
2 Terminated A First Time in Human Study Exploring Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2618960 in Healthy Volunteers and Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: Part A: 100 mg/mL GSK2618960;   Drug: Part A: matching placebo;   Drug: Part B: Dose of GSK2618960 decided from Part A;   Drug: Part B: matching placebo;   Drug: Part C: Dose of GSK2618960 decided from Part A and B
3 Recruiting A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)
Condition: Multiple Sclerosis
Interventions: Biological: PF-06342674 0.25 mg/kg;   Biological: Placebo;   Biological: PF-06342674 1.5 mg/kg;   Biological: PF-06342674 6.0 mg/kg
4 Recruiting Genetic Basis of Primary Immunodeficiencies
Condition: Immunologic Deficiency Syndrome
Intervention:
5 Unknown  Effects of High Cut-off (HCO) Hemodialysis on Central Memory CD4+ T and Treg Cells in Patients With End-stage Kidney Disease
Conditions: End-stage Kidney Disease;   CD4 T Cells;   Central Memory T Cells;   Regulatory T Cells;   Uremic Toxins
Intervention: Device: Polyamide HD membrane

Indicates status has not been verified in more than two years